Literature DB >> 8318427

pS2 is an independent factor of good prognosis in primary breast cancer.

A M Thompson1, R A Hawkins, R A Elton, C M Steel, U Chetty, D C Carter.   

Abstract

In breast cancer, oestrogen regulated genes, such as pS2, may be expressed in well differentiated tumours with a good prognosis. We have examined pS2 mRNA expression in 78 primary, untreated breast cancers and related pS2 expression to disease behaviour and known prognostic factors. pS2 mRNA expression was detected in 25/78 (32%) of cancers and was significantly associated with a moderate/high oestrogen receptor content (P = 0.045, Chi Square test). pS2 mRNA expression was associated with freedom from disease at median 31 months clinical and radiological follow-up (P = 0.015, Fisher's exact test, odds ratio 8.6). Using multiple logistic regression analysis of six potential prognostic factors only pathological axillary node status (P < 0.01) and pS2 mRNA expression (P < 0.05) provided independent prognostic information. Furthermore, pS2 was associated with a good prognosis in the axillary node positive patients where only 1/13 (8%) with pS2 mRNA expression compared with 13/29 (45%) without detectable expression had recurrence of their disease. These data provides strong support for pS2 as a useful independent prognostic factor in primary breast cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8318427      PMCID: PMC1968288          DOI: 10.1038/bjc.1993.292

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Establishment and characterization of a cell line of human breast carcinoma origin.

Authors:  I Keydar; L Chen; S Karby; F R Weiss; J Delarea; M Radu; S Chaitcik; H J Brenner
Journal:  Eur J Cancer       Date:  1979-05       Impact factor: 9.162

2.  Effects of tamoxifen and 4-hydroxytamoxifen on the pNR-1 and pNR-2 estrogen-regulated RNAs in human breast cancer cells.

Authors:  F E May; B R Westley
Journal:  J Biol Chem       Date:  1987-11-25       Impact factor: 5.157

3.  Detection of estradiol-induced messenger RNA (pS2) in uninvolved breast tissue from mastectomies for breast cancer.

Authors:  E Hähnel; R Joyce; G Sterrett; J Harvey; R Hähnel
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

4.  A human cell line from a pleural effusion derived from a breast carcinoma.

Authors:  H D Soule; J Vazguez; A Long; S Albert; M Brennan
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

5.  Structure of the human oestrogen-responsive gene pS2.

Authors:  J M Jeltsch; M Roberts; C Schatz; J M Garnier; A M Brown; P Chambon
Journal:  Nucleic Acids Res       Date:  1987-02-25       Impact factor: 16.971

6.  Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7.

Authors:  S B Jakowlew; R Breathnach; J M Jeltsch; P Masiakowski; P Chambon
Journal:  Nucleic Acids Res       Date:  1984-03-26       Impact factor: 16.971

7.  Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line.

Authors:  P Masiakowski; R Breathnach; J Bloch; F Gannon; A Krust; P Chambon
Journal:  Nucleic Acids Res       Date:  1982-12-20       Impact factor: 16.971

8.  Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7.

Authors:  A M Brown; J M Jeltsch; M Roberts; P Chambon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

9.  Mouse actin messenger RNAs. Construction and characterization of a recombinant plasmid molecule containing a complementary DNA transcript of mouse alpha-actin mRNA.

Authors:  A J Minty; M Caravatti; B Robert; A Cohen; P Daubas; A Weydert; F Gros; M E Buckingham
Journal:  J Biol Chem       Date:  1981-01-25       Impact factor: 5.157

10.  Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA.

Authors:  C Auffray; F Rougeon
Journal:  Eur J Biochem       Date:  1980-06
View more
  7 in total

1.  Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.

Authors:  S J Reshkin; T Tedone; M Correale; A Mangia; V Casavola; A Paradiso
Journal:  Cell Prolif       Date:  1999 Apr-Jun       Impact factor: 6.831

2.  pS2 expression induced by American ginseng in MCF-7 breast cancer cells.

Authors:  R B Duda; B Taback; B Kessel; D D Dooley; H Yang; J Marchiori; B M Slomovic; J G Alvarez
Journal:  Ann Surg Oncol       Date:  1996-11       Impact factor: 5.344

3.  Immunohistochemical determination of pS2 in invasive breast carcinomas: a study on 942 cases.

Authors:  I Soubeyran; J Wafflart; F Bonichon; I de Mascarel; M Trojani; M Durand; A Avril; J M Coindre
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

4.  PS2 mRNA expression adds prognostic information to node status for 6-year survival in breast cancer.

Authors:  A M Thompson; R A Elton; R A Hawkins; U Chetty; C M Steel
Journal:  Br J Cancer       Date:  1998       Impact factor: 7.640

5.  pS2 and response to adjuvant hormone therapy in primary breast cancer.

Authors:  F Spyratos; C Andrieu; K Hacène; P Chambon; M C Rio
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

6.  Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators.

Authors:  M A Levesque; G M Clark; H Yu; E P Diamandis
Journal:  Br J Cancer       Date:  1995-09       Impact factor: 7.640

7.  Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.

Authors:  J A Foekens; H Portengen; M P Look; W L van Putten; B Thirion; M Bontenbal; J G Klijn
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.